FindTrial
Sign In

To evaluate effect of immunotherapy .

To evaluate effect of immunotherapy on clinical parameters using PET CT Scan in patients diagnosed with metastatic or recurrent unresectable head and neck cancer-a retrospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062655
Enrollment
10
Registered
2024-02-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Control Intervention1: NIL: NIL

Sponsors

HCG NCHRI Cancer Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Recurrent and Metastatic head and neck cancer patients who received Immunotherapy from September 2022 to September 2023

Exclusion criteria

Exclusion criteria: study does not have exclusion criteria

Design outcomes

Primary

MeasureTime frame
to measure overall survival rate, duration of response and progression free survivalTimepoint: After starting immunotherapy, every three weeks—

Secondary

MeasureTime frame
NOT APPLICABLETimepoint: NOT APPLICABLE—

Countries

India

Contacts

Public ContactDr Nidhi Hari

HCG-NCHRI Cancer Centre

drnidhihariomfs@gmail.com8197647491

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026